Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers

Leuk Lymphoma. 2018 Aug;59(8):1949-1958. doi: 10.1080/10428194.2017.1403022. Epub 2018 Jan 3.


The course of chronic lymphocytic leukemia (CLL), inducing an immunosuppressed state that also affects T cells as central components of adaptive immunity, predisposes patients to develop second malignancies with skin cancer being the most common. Recently, we found that prevalence of memory T cells with specificity for CLL-associated antigens defined by mass spectrometry-based immunopeptidome analysis correlated with a significant survival benefit. Here, we analyzed our CLL patient cohort for second skin (pre)malignancies and found a significantly lower incidence of skin cancer in the patients showing immune responses to CLL-associated antigens. Surprisingly, CLL-associated antigen-specific immune responses did not associate with clinical characteristics including leukocyte, neutrophil, and thrombocyte count, hemoglobin, immunoglobulin levels, or CD8+ and CD4+ T-cell immune status. Our data indicate that the CLL-specific immune signature of a given patient, defined by antigen-specific T-cell responses, might represent an independent marker to identify CLL patients susceptible for the development of skin malignancies.

Keywords: Chronic lymphocytic leukemia; T-cell response; antigen; second malignancies; skin cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens / immunology*
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / immunology*
  • Precancerous Conditions / immunology
  • Risk Factors
  • Skin Neoplasms / immunology*
  • T-Lymphocytes / immunology*


  • Antigens